Reuters logo
BRIEF-Diffusion Pharma gets FDA protocol guidance for phase 3 trial with TSC
2017年10月17日 / 中午12点08分 / 1 个月前

BRIEF-Diffusion Pharma gets FDA protocol guidance for phase 3 trial with TSC

Oct 17 (Reuters) - Diffusion Pharmaceuticals Inc

* Diffusion Pharmaceuticals receives final FDA protocol guidance for phase 3 clinical trial with TSC in patients newly diagnosed with inoperable glioblastoma multiforme

* Has responded to all outstanding points raised by FDA, plans to begin trial under protocol agreed to by FDA by end of 2017​

* Trial to compare survival at 2 yrs of patients receiving TSC concurrent with chemo, radiation with patients receiving SOC alone​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below